Setrusumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Setrusumab
Accession Number
DB14778
Type
Biotech
Groups
Investigational
Description

Setrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).

Synonyms
Not Available
External IDs
BPS804
Categories
UNII
FPW3780T3E
CAS number
1847394-95-9

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Setrusumab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Setrusumab.
AbrilumabThe risk or severity of adverse effects can be increased when Setrusumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Setrusumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Setrusumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Setrusumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Setrusumab.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Setrusumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Setrusumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Setrusumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentOsteogenesis Imperfecta Type III / Osteogenesis Imperfecta Type IV / Osteogenesis Imperfecta, Type I1
2CompletedTreatmentHypophosphatasia1
2CompletedTreatmentOsteogenesis Imperfecta1
2CompletedTreatmentOsteopenia / Osteoporosis1
2WithdrawnTreatmentChronic-kidney Disease Stage 5D on Stable Hemodialysis1
2WithdrawnTreatmentOsteogenesis Imperfecta1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:26 / Updated on May 21, 2019 12:29